Susan Hayes Culleton

I'm great, all together.

And I'm going to, first of all, go to the release of the Financial Stability Review this week, Aidan, when the ECB Vice President said, markets are discounting a very benign scenario that AI is going to be fully implemented and adopted all over the world.

Is he right?

But Aidan, if we look, let's just take the Magnificent Seven.

Is anybody really making money out of AI apart from NVIDIA at the moment?

And of course, we are seeing generative, then we're moving into agentic and there's a range of others as well.

But I also want to ask, big tech is now a third of the S&P 500, but Aidan, there are 7 million companies in America.

What is the focus on AI distracting us from?

Aidan, all year we've been waiting for the tariff impact to hit the bottom line of companies.

And of course, when we put the focus on markets, we're focusing on companies that export.

Based on your conversations with those companies, are they now feeling the impact, particularly in the wholesale market, in the industrials?

Well, that certainly is one way of doing it is simply call it a tariff surcharge.

And when you were there since it was a little while ago, the government shutdown was happening.

Do you think that that will have a lasting impact on businesses or will they simply adjust because it's over now?

And also, can I look at one other area as well?

Eli Lilly last week was the first pharma company to join the Trillion Dollar Club.

And this week, the US government has negotiated a 71% discount for Novo Nordisk's weight loss drug Ozempic and Wagovi for patients enrolled in Medicare.

What's next, do you think, for the weight loss drug equity play?

And while you say Nova Nordic has had a tough year Aidan it's had a tough week as well because of the results from the Alzheimer's drug as well so in the fortunes of that company as it's looking into 2026 what do you think?

Aidan Donnelly from Davey, thank you very much indeed for joining us this morning on Business Breakfast.